Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments

Yumi Yasukochi, Takeshi Nakahara, Takeru Abe, Makiko Kido-Nakahara, Futoshi Kohda, Satoshi Takeuchi, Akihito Hagihara, Masutaka Furue

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    Background: Serum thymus and activation-regulated chemokine (TARC) levels are associated with the disease activity of patients with atopic dermatitis (AD) and sensitively reflect short-term changes in skin conditions. The main treatment for AD is topical agent application.

    Objective: This study investigated the relationship between serum TARC levels and the dosage of topical agents, including corticosteroids and/or tacrolimus, in patients with AD.

    Methods: The serum TARC levels of 56 AD patients and the amounts of topical agents prescribed to them were investigated retrospectively. The weekly reduction in serum TARC levels and weekly dosage of topical agents among AD patients were compared and their associations were evaluated.

    Results: The dosage of topical agents was closely related to serum TARC levels. One gram of strong rank steroid or the equivalent amount of steroid/tacrolimus is required to reduce serum TARC levels by 9.94 pg/mL weekly in moderate to severe AD patients. Higher initial TARC levels require more topical agent, which results in a more rapid decrease in TARC levels. The serum TARC levels and eosinophil numbers in peripheral blood are significantly correlated.

    Conclusion: Serum TARC level improvement and topical agent dosage are strongly correlated. TARC and eosinophil numbers are significantly correlated, but the wider range of TARC levels seems to be clinically more useful for monitoring AD severity. The serum TARC level is a very sensitive biomarker for monitoring the severity and treatment response in AD.

    Original languageEnglish
    Pages (from-to)240-245
    Number of pages6
    JournalAsian Pacific Journal of Allergy and Immunology
    Volume32
    Issue number3
    DOIs
    Publication statusPublished - 2014 Sep 1

    Fingerprint

    Chemokine CCL17
    Atopic Dermatitis
    Anti-Inflammatory Agents
    Serum
    Therapeutics
    Tacrolimus
    Eosinophils
    Steroids

    Keywords

    • Atopic dermatitis
    • Serum thymus and activation-regulated chemokine (TARC) levels
    • Topical corticosteroids
    • Topical tacrolimus
    • Total equivalent amounts (TEA)

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology
    • Medicine(all)

    Cite this

    Yasukochi, Y., Nakahara, T., Abe, T., Kido-Nakahara, M., Kohda, F., Takeuchi, S., ... Furue, M. (2014). Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments. Asian Pacific Journal of Allergy and Immunology, 32(3), 240-245. https://doi.org/10.12932/AP0419.32.3.2014

    Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments. / Yasukochi, Yumi; Nakahara, Takeshi; Abe, Takeru; Kido-Nakahara, Makiko; Kohda, Futoshi; Takeuchi, Satoshi; Hagihara, Akihito; Furue, Masutaka.

    In: Asian Pacific Journal of Allergy and Immunology, Vol. 32, No. 3, 01.09.2014, p. 240-245.

    Research output: Contribution to journalArticle

    Yasukochi, Y, Nakahara, T, Abe, T, Kido-Nakahara, M, Kohda, F, Takeuchi, S, Hagihara, A & Furue, M 2014, 'Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments', Asian Pacific Journal of Allergy and Immunology, vol. 32, no. 3, pp. 240-245. https://doi.org/10.12932/AP0419.32.3.2014
    Yasukochi, Yumi ; Nakahara, Takeshi ; Abe, Takeru ; Kido-Nakahara, Makiko ; Kohda, Futoshi ; Takeuchi, Satoshi ; Hagihara, Akihito ; Furue, Masutaka. / Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments. In: Asian Pacific Journal of Allergy and Immunology. 2014 ; Vol. 32, No. 3. pp. 240-245.
    @article{f994e327bc6e47149e084f450695ead6,
    title = "Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments",
    abstract = "Background: Serum thymus and activation-regulated chemokine (TARC) levels are associated with the disease activity of patients with atopic dermatitis (AD) and sensitively reflect short-term changes in skin conditions. The main treatment for AD is topical agent application.Objective: This study investigated the relationship between serum TARC levels and the dosage of topical agents, including corticosteroids and/or tacrolimus, in patients with AD.Methods: The serum TARC levels of 56 AD patients and the amounts of topical agents prescribed to them were investigated retrospectively. The weekly reduction in serum TARC levels and weekly dosage of topical agents among AD patients were compared and their associations were evaluated.Results: The dosage of topical agents was closely related to serum TARC levels. One gram of strong rank steroid or the equivalent amount of steroid/tacrolimus is required to reduce serum TARC levels by 9.94 pg/mL weekly in moderate to severe AD patients. Higher initial TARC levels require more topical agent, which results in a more rapid decrease in TARC levels. The serum TARC levels and eosinophil numbers in peripheral blood are significantly correlated.Conclusion: Serum TARC level improvement and topical agent dosage are strongly correlated. TARC and eosinophil numbers are significantly correlated, but the wider range of TARC levels seems to be clinically more useful for monitoring AD severity. The serum TARC level is a very sensitive biomarker for monitoring the severity and treatment response in AD.",
    keywords = "Atopic dermatitis, Serum thymus and activation-regulated chemokine (TARC) levels, Topical corticosteroids, Topical tacrolimus, Total equivalent amounts (TEA)",
    author = "Yumi Yasukochi and Takeshi Nakahara and Takeru Abe and Makiko Kido-Nakahara and Futoshi Kohda and Satoshi Takeuchi and Akihito Hagihara and Masutaka Furue",
    year = "2014",
    month = "9",
    day = "1",
    doi = "10.12932/AP0419.32.3.2014",
    language = "English",
    volume = "32",
    pages = "240--245",
    journal = "Asian Pacific Journal of Allergy and Immunology",
    issn = "0125-877X",
    publisher = "The Allergy and Immunology Society of Thailand",
    number = "3",

    }

    TY - JOUR

    T1 - Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments

    AU - Yasukochi, Yumi

    AU - Nakahara, Takeshi

    AU - Abe, Takeru

    AU - Kido-Nakahara, Makiko

    AU - Kohda, Futoshi

    AU - Takeuchi, Satoshi

    AU - Hagihara, Akihito

    AU - Furue, Masutaka

    PY - 2014/9/1

    Y1 - 2014/9/1

    N2 - Background: Serum thymus and activation-regulated chemokine (TARC) levels are associated with the disease activity of patients with atopic dermatitis (AD) and sensitively reflect short-term changes in skin conditions. The main treatment for AD is topical agent application.Objective: This study investigated the relationship between serum TARC levels and the dosage of topical agents, including corticosteroids and/or tacrolimus, in patients with AD.Methods: The serum TARC levels of 56 AD patients and the amounts of topical agents prescribed to them were investigated retrospectively. The weekly reduction in serum TARC levels and weekly dosage of topical agents among AD patients were compared and their associations were evaluated.Results: The dosage of topical agents was closely related to serum TARC levels. One gram of strong rank steroid or the equivalent amount of steroid/tacrolimus is required to reduce serum TARC levels by 9.94 pg/mL weekly in moderate to severe AD patients. Higher initial TARC levels require more topical agent, which results in a more rapid decrease in TARC levels. The serum TARC levels and eosinophil numbers in peripheral blood are significantly correlated.Conclusion: Serum TARC level improvement and topical agent dosage are strongly correlated. TARC and eosinophil numbers are significantly correlated, but the wider range of TARC levels seems to be clinically more useful for monitoring AD severity. The serum TARC level is a very sensitive biomarker for monitoring the severity and treatment response in AD.

    AB - Background: Serum thymus and activation-regulated chemokine (TARC) levels are associated with the disease activity of patients with atopic dermatitis (AD) and sensitively reflect short-term changes in skin conditions. The main treatment for AD is topical agent application.Objective: This study investigated the relationship between serum TARC levels and the dosage of topical agents, including corticosteroids and/or tacrolimus, in patients with AD.Methods: The serum TARC levels of 56 AD patients and the amounts of topical agents prescribed to them were investigated retrospectively. The weekly reduction in serum TARC levels and weekly dosage of topical agents among AD patients were compared and their associations were evaluated.Results: The dosage of topical agents was closely related to serum TARC levels. One gram of strong rank steroid or the equivalent amount of steroid/tacrolimus is required to reduce serum TARC levels by 9.94 pg/mL weekly in moderate to severe AD patients. Higher initial TARC levels require more topical agent, which results in a more rapid decrease in TARC levels. The serum TARC levels and eosinophil numbers in peripheral blood are significantly correlated.Conclusion: Serum TARC level improvement and topical agent dosage are strongly correlated. TARC and eosinophil numbers are significantly correlated, but the wider range of TARC levels seems to be clinically more useful for monitoring AD severity. The serum TARC level is a very sensitive biomarker for monitoring the severity and treatment response in AD.

    KW - Atopic dermatitis

    KW - Serum thymus and activation-regulated chemokine (TARC) levels

    KW - Topical corticosteroids

    KW - Topical tacrolimus

    KW - Total equivalent amounts (TEA)

    UR - http://www.scopus.com/inward/record.url?scp=84911927615&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84911927615&partnerID=8YFLogxK

    U2 - 10.12932/AP0419.32.3.2014

    DO - 10.12932/AP0419.32.3.2014

    M3 - Article

    VL - 32

    SP - 240

    EP - 245

    JO - Asian Pacific Journal of Allergy and Immunology

    JF - Asian Pacific Journal of Allergy and Immunology

    SN - 0125-877X

    IS - 3

    ER -